EXHIBIT 10.45

 

AMENDMENT NO. 1

to the July 17, 2002

RESEARCH AGREEMENT

 

This AMENDMENT NO. 1 (the “Amendment”) to the July 17, 2002 RESEARCH AGREEMENT
(the “Agreement”) is entered into as of April 17, 2003 (the “Amendment Effective
Date”) by and between GENENTECH and ACLARA. Unless otherwise noted, all defined
terms set forth in this Amendment shall have the same meaning as set forth in
the Agreement.

 

RECITALS

 

1.    ACLARA and GENENTECH entered into the Agreement on July 17, 2002, under
which the Parties conducted Stage I of the Study.

 

2.    The Parties, having completed the research described in Stage I of the
Study, desire to conduct additional research as set forth in Exhibit A1,
attached hereto and incorporated herein.

 

NOW, THEREFORE, ACLARA and GENENTECH hereby agree to amend the Agreement as
follows:

 

A.   The term “Study” shall include both the research originally set forth in
Exhibit A attached to the Agreement (referred to herein as “Stage I”) and the
additional research set forth in Exhibit A1 attached to this Amendment [ * ].

 

B.   Section 1(e) of the Agreement shall be deleted and replaced with the
following: “Term of Study” means a period commencing on the Effective Date and
ending upon the delivery of the Aclara Results, as set forth in section 9
herein, [ * ].

 

C.   Section 1(f) of the Agreement shall be deleted and replaced with the
following: [ * ] developed under the Study incorporating Aclara Technology that
is directed to [ * ] including [ * ].

 

D.   Section 4 of the Agreement shall be deleted in its entirety and replaced
with the following:

 

4.    Payments and [ * ].

 

(a) In consideration of ACLARA’s [ * ] performing the Study, GENENTECH shall,
subject to the conditions noted below, make the following non-refundable
payments to ACLARA by wire transfer:

 

Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as [ * ]. A complete version of this exhibit has been
filed separately with the Securities and Exchange Commission.

--------------------------------------------------------------------------------

1. Within 30 days of execution of the original Agreement   
$[ * ] (already paid as of the Amendment Effective Date) 2. Within 30 days of
delivery of [ * ] to GENENTECH    $[ * ] (already paid as of the Amendment
Effective Date) 3. Within 30 days of execution of this Amendment    $[ * ] 4.
Within 30 days of delivery of [ * ] to GENENTECH    $[ * ] 5. Within 30 days of
GENENTECH’s written notice to ACLARA [ * ]    $[ * ] 6. Within 30 days of
delivery of [ * ] to GENENTECH    $[ * ]

 

It is understood that, following delivery of [ * ] to GENENTECH, GENENTECH shall
determine whether or not it wishes to [ * ] by written notice to ACLARA within
thirty (30) days [ * ].

 

(b) GENENTECH shall [ * ].

 

Such [ * ] following delivery of Aclara Results regarding the Stage II research
to GENENTECH and, upon GENENTECH [ * ] by written notice to ACLARA and election
to proceed with Stage III research, GENENTECH shall pay to ACLARA a [ * ] fee of
[ * ] ($[ * ]) within 30 days of such notice, and the parties shall diligently
negotiate in good faith the terms of the License and Co-Development Agreement
until [ * ]. In the event the parties are not able to reach mutually agreeable
terms within such [ * ] period, after such exclusivity period ACLARA shall be
free to supply ACLARA Materials and/or license ACLARA Technology to any Third
Party. The terms of such agreement shall be negotiated in good faith between the
parties, shall take into account the relative contributions of each party and
shall include terms that are normal and customary in the industry.

 

E.   The first half of the first sentence of Section 9 shall be amended as
follows (additions in italics): Upon completion of the [ * ] Study, ACLARA shall
provide a written report of the results of the Study [ * ], and upon completion
[ * ], ACLARA shall provide a written report (either in Word or Power Point
format) of the results of the additional research, each of which [ * ];

 

--------------------------------------------------------------------------------

 

[ * ] Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

2

--------------------------------------------------------------------------------

In addition, the following language shall be added between the first and second
sentence in Section 9: Aclara Results regarding [ * ] were presented to
Genentech [ * ]. It is anticipated that Aclara Results [ * ] will be provided to
Genentech [ * ] of this Amendment and that Aclara Results [ * ].

 

F.   The second sentence of Section 18 shall be amended as follows (additions in
italics): Sections 4(b) and 7 through 16 shall survive expiration or termination
of this Agreement for any reason.

 

IN WITNESS WHEREOF, the undersigned represent that they are duly authorized to
execute this Amendment.

 

ACLARA Biosciences, Inc.       Genentech, Inc. By:  

/s/    Dennis W. Harris        

--------------------------------------------------------------------------------

      By:  

/s/    Joseph S. McCracken        

--------------------------------------------------------------------------------

Name:  

Dennis W. Harris

--------------------------------------------------------------------------------

      Name:  

Joseph S. McCracken

--------------------------------------------------------------------------------

Title:  

Sr. VP Business Development

--------------------------------------------------------------------------------

      Title:  

VP Business & Commercial Dev.

--------------------------------------------------------------------------------

Date:  

April 17, 2003

--------------------------------------------------------------------------------

      Date:  

April 17, 2003

--------------------------------------------------------------------------------

 

 

--------------------------------------------------------------------------------

 

[ * ] Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

 

3

--------------------------------------------------------------------------------

Exhibit 1A

 

[ * ] Research Plans

 

Technology Development Goals:

 

[ * ]

 

Materials provided by Genentech:

 

[ * ]

 

Experimental Goals:

 

[ * ]

 

(subject to modification [ * ])

 

Materials provided by Genentech:

 

--------------------------------------------------------------------------------

 

[ * ] Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

4